BeiGene responds to being sued again by AbbVie: denies allegations and will launch a firm defense
因醉鞭名马幌
发表于 2024-9-24 23:51:43
199
0
0
Southern Finance and Economics, September 12th - According to Interface News and Fierce Biotech, multinational pharmaceutical company AbbVie has recently sued BeiGene again for plagiarizing the trade secrets of its BTK degrader. BeiGene stated that it has been informed that AbbVie has recently filed a lawsuit against our company, which includes the compound BGB-16673 independently discovered by BeiGene. BeiGene will vigorously defend itself against the allegations made by AbbVie. The company is currently carefully reviewing AbbVie's allegations and will respond appropriately through legal procedures.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Baekje Shenzhou Tirelizumab has been approved for marketing by the FDA
- BeiGene: Tirelizumab Approved for Market by FDA
- Luckin Coffee v. Shenzhou Youche Case Goes to Court Today
- BeiGene: Chief Financial Officer Wang Aijun Resigns, Aaron Rosenberg Takes Over
- BeiGene (688235. SH): Chief Financial Officer Wang Aijun resigns due to seeking external development opportunities
- BeiGene Chief Financial Officer Resigns, Aaron Rosenberg Takes Over
- BeiGene responds to investigation of company executives: the incident involving the employee has nothing to do with BeiGene
- BeiGene: An employee of the company is cooperating with the investigation and it is understood that the incident in question is not related to BeiGene
- BeiGene responds to employee cooperation investigation: the incident is not related to the company